Grants and Contributions:

Title:
Medicago Inc. COVID-19
Agreement Number:
815733
Agreement Value:
$173,000,000.00
Agreement Date:
Oct 18, 2020 - Aug 1, 2040
Description:
The Project is in direct response to the global fight against COVID-19. The Project will be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:

The direct and immediate benefit of the project's first stage is the rapid development of a plant-based vaccine that may lead to an effective vaccine for COVID-19, and thus, help prevent the spread. The second stage, building a GMP facility that can manufacture vaccine and antibodies, is expected to increase biomanufacturing capabilities and build on areas of strength and technological advantage to advance Canada’s life science’s industry.

Location:
Quebec, Quebec, CA G1V3V9
Reference Number:
230-2020-2021-Q3-0143
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
872308499
Recipient Type:
For-profit organization
Additional Information:

This is a repayable contribution.

Recipient's Operating Name:
Medicago inc.
Recipient's Legal Name:
Medicago inc.
Federal Riding Name:
Louis-Hébert
Federal Riding Number:
24044
Program:
SIF Stream3 - Attraction
Program Purpose:

The Strategic Innovation Fund (SIF) attracts and supports new high-quality business investments. In allocating funding, SIF looks to accelerate areas of economic strength, strengthen and expand the role of Canadian firms in regional and global supply chains, support economic strategies, and attract investment that creates new, good, well-paying jobs.

NAICS Code:
53